Introduction
============

Coronary heart disease (CHD), synonymously called coronary artery disease (CAD) is the most predominant among the cardiovascular diseases. Multiple factors, including genetic, environmental, and psychological factors, were believed to contribute to the onset of CHD.[@b1-cia-9-857] The majority of CHD cases could be explained by the interaction of genetic and environmental factors.[@b2-cia-9-857],[@b3-cia-9-857] However, at an individual level there is wide variation in both the occurrence of CHD and the age of manifestation, even in individuals with the same risk factor profiles. Given that CHD is an age-related disease, the hypothesis has been proposed that inter-individual variation in risk of CHD might come from variation in the rate of biological aging.[@b4-cia-9-857]--[@b6-cia-9-857] Telomeres are the protein-bound DNA repeat structures at the ends of chromosomes that play an important role in maintaining genomic stability. They are critical in regulating cellular replicative capacity, and are always deemed as a marker of biological aging.[@b7-cia-9-857]--[@b10-cia-9-857] In a large, cross-sectional study, mean leucocyte telomere length (LTL) was found to be a predictor of future CHD events in middle-aged, high-risk men and might be able to identify individuals who would benefit most from statin treatment.[@b4-cia-9-857] This supports the hypothesis that differences in biological aging might contribute to the risk and variability in age of the onset of CHD.[@b5-cia-9-857],[@b6-cia-9-857] A recent genome-wide meta-analysis identified seven loci involved in telomere biology, including rs10936599 in TERC, rs2736100 in TERT, rs7675998 in NAF1, rs9420907 in OBFC1, rs8105767 in ZNF208, rs755017 in RTEL1, and rs11125529 in ACYP2, and the subsequent large, case-control study confirmed the association between shorter LTL and increased risk of coronary artery disease (21% \[95% confidence interval, 5%--35%\] per standard deviation in LTL, *P*=0.014) in those of European descent.[@b11-cia-9-857] The aim of this study is to replicate these previously confirmed telomere-length loci in a Chinese Han population with CHD.

Materials and methods
=====================

Study subjects
--------------

1514 CHD patients and 2470 normal controls were recruited from a single province (Jiangsu Province) in the People's Republic of China. CHD was diagnosed by angiography, which was defined as the presence of at least one significant coronary artery stenosis of ≥50% luminal diameter on coronary angiography. For normal controls, the criteria were no history of CAD or electrocardiographic signs of CAD. All participants were Han ethnic. Patients with myocardial bridge, congenital heart diseases, or other types of atherosclerotic lesions were excluded from the study. The individuals in the CHD and control groups were all unrelated, and identity information of all the subjects has been critically reviewed.

Data and sample collections
---------------------------

Medical data including age, sex, body mass index (BMI), lipid profiles, history of hypertension, type 2 diabetes mellitus, and dyslipidemia were collected from all the participants. The BMI was calculated as the weight (kg) divided by the corrected height (m) squared (kg/m^2^). Rest electrocardiograms (ECG) were performed for the control participants. All control participants showed no signs of CHD, hypertension, diabetes mellitus, or dyslipidemia based on the ECG results and medical-case files at the time of enrollment. Total cholesterol (TC), total triglyceride (TG), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), apolipoprotein (apo)AI, apoB, lipoprotein (Lp\[a\]), and C reactive protein (CRP) were measured by standard techniques.

Selection of single-nucleotide polymorphisms
============================================

Seven previously identified single-nucleotide polymorphisms (SNPs) related to LTL were genotyped, including rs10936599 in TERC, rs2736100 in TERT, rs7675998 in NAF1, rs9420907 in OBFC1, rs8105767 in ZNF208, rs755017 in RTEL1, and rs11125529 in ACYP2.

Genotyping
----------

Approved by the ethics committees of The Affiliated Yixing People's Hospital, Jiangsu University, blood samples were collected for DNA analysis, with informed consent obtained from the participants. Standard protocols were used to extract genomic DNA from blood leukocytes. Genotyping was performed using polymerase chain reaction (PCR)-based Invader assay with the probe sets designed and synthesized by Third Wave (Shanghai, People's Republic of China). The genotyping results were read with an ABI PRISM7900HT sequence detection system (Applied Biosystems, Foster City, CA, USA). Twenty percent of the samples were selected randomly to validate the reproducibility of the genotyping results, with 100% reproducibility. Two authors independently reviewed the genotyping results, data entry, and statistical analysis.

Statistical analysis
--------------------

Data were analyzed using SPSS software (SPSS Inc., Chicago, IL, USA, version 13.0). Data are expressed as the mean ± standard deviation (SD). The significance of differences was evaluated using the Student's *t*-test for continuous variables and the *χ*^2^ test for non-continuous variables. The *χ*^2^ test was used to examine differences of allelic frequencies and genotype distributions between the CHD patients and the controls. The Hardy--Weinberg equilibrium was tested by a goodness-of-fit *χ*^2^ test. Odds ratios (ORs) of the significant associated SNPs were calculated using the non-risk allele as a reference. Multivariate analysis was performed using a logistic regression analysis for independent variables that were related to the presence or absence of CHD. A one-way analysis of variance (ANOVA) test was used to compare the mean onset age of different genotypes in case-only analyses. Statistical significance was set at *P*\<0.05.

Results
=======

Characteristics of study subjects
---------------------------------

Clinical characteristics of the CHD patients and control subjects are shown in [Table 1](#t1-cia-9-857){ref-type="table"}. The proportion of males, average age, and BMI were all significantly higher in the CHD patients than in the controls. The ratios of hypertension, diabetes, and hyperlipidemia were higher in the CHD patients than in the controls. Plasma concentrations of LDL-C and HDL-C were significantly lower, while TC, TG, and Lp(a) were significantly higher in the CHD group compared to the control group. No differences in ApoA1 and ApoB were found between the two groups.

Case-control association analysis
---------------------------------

No significant difference in genotype frequencies from the Hardy--Weinberg equilibrium test was noted for any tested SNPs, both in the CHD patients and the normal controls. No polymorphism was observed for rs9420907, and the AA genotype was noted in both the CHD patients and the controls. Neither the genotype nor the allele frequencies of rs2736100, rs8105767, rs11125529, and rs2967374 were significantly different between the CHD patients and the normal controls ([Table 2](#t2-cia-9-857){ref-type="table"}). For rs10936599 and rs755017, a statistically significant difference was found for the allele frequency but not the genotype. Distributions of genotype and allele were significantly different between the two groups for rs7675998. The ORs for carriers for CHD of each allele are listed in [Table 3](#t3-cia-9-857){ref-type="table"}.

Case-only association study
---------------------------

By one-way ANOVA test, rs7675998 was associated with the onset age of CHD. CHD patients with the AA genotype of rs7675998 had significantly lower age of onset (*P*\<0.05; [Table 4](#t4-cia-9-857){ref-type="table"}).

Discussion
==========

Telomeres are the extreme ends of chromosomal DNA, playing a critical role in maintaining genomic stability by regulating cellular replicative capacity.[@b12-cia-9-857]--[@b14-cia-9-857] Due to the inability of DNA polymerase to fully complete the replication of the 3′ end of linear DNA, telomeres progressively shorten with repeated cell division.[@b13-cia-9-857] Once a critically short telomere length is reached, the cell is triggered to enter replicative senescence, which subsequently leads to cell death.[@b14-cia-9-857] Therefore, mean telomere length could serve as a marker for biological age, at least at the cellular level, with shorter telomeres indicating increased biological age.[@b10-cia-9-857],[@b15-cia-9-857] CHD is an age-related disease and many studies have confirmed the consolidate association between leukocyte telomere length and CHD.[@b4-cia-9-857]--[@b6-cia-9-857] CHD is a complex, multifactorial disorder involving multiple environmental risks and genetic factors, and LTL was found to be related to many of these factors.[@b1-cia-9-857] CHD is a chronic inflammatory process and the shorter telomere length in individuals prone to CHD could simply indicate a greater white blood cell turnover.[@b16-cia-9-857]--[@b18-cia-9-857] Increased oxidative stress was another factor contributing to atherosclerosis, and increased oxidant stress has been shown to increase rates of telomere attrition in vitro.[@b19-cia-9-857]--[@b21-cia-9-857] Other risk factors of CHD, including smoking, high BMI, and type 1 diabetes mellitus, were also associated with shorter LTL.[@b22-cia-9-857]--[@b24-cia-9-857] As to psychological aspects, life stress and job insecurity have been implicated in the etiology of CHD.[@b3-cia-9-857],[@b25-cia-9-857] Recent studies have demonstrated a strong correlation between life stress and shorter LTL.[@b26-cia-9-857] In a word, shorter LTL may pose cumulative effects on pathogenesis of CHD.

LTL is significantly variable among individuals, and was thought to be determined genetically.[@b11-cia-9-857] It is believed that those individuals who have inherited and are born with shorter telomeres might be more prone to some certain diseases. Two loci on chromosome 3q26 (*TERC*) and chromosome 10q24.33 (*OBFC1*) have shown an association with mean LTL in a genome-wide association study (GWAS).[@b11-cia-9-857] In a subsequent GWAS with more cases, five new loci were also associated with LTL, and showed an association with increased risks of CHD.[@b11-cia-9-857] From the viewpoint of population genetics, generalization of LTL association results previously identified in European GWA studies (or meta-analyses) to non-European populations is an interesting issue, because it can facilitate the fine mapping of common causal variants by providing clues as to whether SNPs identified in European GWA studies are simply tag-SNP or "synthetic association" markers, or if they are more likely to be true functional variants. The aforementioned two GWASs were both conducted in people of European descent; now, we have performed the first replication study in a Chinese Han population. In the original study, combined analysis demonstrated a strong association between alleles associated with shorter LTL and higher risk of CHD, but individually the lead SNPs at each of the telomere length-associated loci were not significantly associated with risk of CHD. However, among these loci, rs7675998 on 4q32.2 (*NAF1*) and rs9420907 chromosome 10q24.33 (*OBFC1*) showed the highest risks (1.43 and 0.41, respectively). Our study reconfirmed the association between rs7675998 and the disease, but no polymorphism was found for rs9420907 in the Chinese Han population. Moreover, in a subgroup analysis, rs7675998 was also found to be related to the onset age of CHD, verifying the hypothesis that those individuals who have inherited and are born with shorter telomeres might be more prone to CHD, and their onset age of CHD may also be determined by LTL.

In conclusion, in a Chinese Han population, *NAF1* gene encoding proteins with known function in telomere biology may influence both the possibility and the onset age of CHD, as previously reported in European studies.
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###### 

The characteristics of the clinical data in comparisons between control and CHD groups

                      CHD patients (n=1,514)   Controls (n=2,470)   *P*-value
  ------------------- ------------------------ -------------------- -----------
  Age (years)         63.7±9.5                 58.6±8.9             0.002
  Sex (male/female)   977/537                  1,562/908            0.41
  BMI (kg/m^2^)       25.8                     24.2                 \<0.01
  Smoking (%)         52.1                     34.3                 \<0.01
  DM (%)              58.4                     42.3                 \<0.01
  Hypertension (%)    25.6                     10.2                 \<0.01
  TC (mmol/L)         5.42±1.03                4.92±0.92            \<0.01
  TG (mmol/L)         1.96±0.72                1.38±0.43            \<0.01
  LDL-C (mmol/L)      3.40±0.54                3.02±0.32            \<0.01
  HDL-C (mmol/L)      1.22±0.81                1.47±0.51            \<0.01
  ApoA1 (g/L)         1.32±0.14                1.30±0.13            0.26
  ApoB (g/L)          0.91±0.21                0.90±0.16            0.52
  Lp(a) (mg/L)        292.48±226.83            43.27±72.63          \<0.01

**Abbreviations:** CHD, coronary heart disease; BMI, body mass index; DM, diabetes mellitus; TC, total cholesterol; TG, total triglyceride; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; Apo, apolipoprotein; Lp(a), lipoprotein.

###### 

Distribution of selected variables among cases and controls in a Han Chinese population

  Genotype     CHD     Control   χ^2^(*P*)   Allele   CHD     Control   χ^2^(*P*)                         
  ------------ ------- --------- ----------- -------- ------- --------- ----------- ------ ------- ------ -------
  rs10936599                                                                                              
   CC          265     17.5      371         15.0     0.08    C         1,298       42.9   2,001   40.5   0.04
   CT          768     50.7      1,259       51.0             T         1,730       57.1   2,939   59.5   
   TT          481     31.8      840         34.0                                                         
  rs2736100                                                                                               
   GG          357     23.6      599         24.3     0.56    G         1,499       49.5   2,436   49.3   0.87
   GT          785     51.8      1,238       50.1             T         1,529       50.5   2,504   50.7   
   TT          372     24.6      633         25.6                                                         
  rs7675998                                                                                               
   AA          145     9.6       50          2.0      0.000   A         889         29.3   815     16.5   0.000
   AG          599     39.6      715         28.9             G         2,139       70.7   4,125   83.5   
   GG          770     50.9      1,705       69.1                                                         
  rs9420907                                                                                               
   AA          1,514   100       2,470       100      N/A     A         3,028       100    4,940   100    N/A
   AC                                                         C                                           
   CC                                                                                                     
  rs8105767                                                                                               
   AA          730     48.2      1,223       49.5     0.73    A         2,124       71.1   3,502   70.9   0.48
   AG          664     43.9      1,056       42.8             G         904         29.9   1,438   29.1   
   GG          120     7.9       191         7.7                                                          
  rs755017                                                                                                
   AA          485     32.0      672         27.2     0.41    A         1,736       57.3   2,598   52.6   0.000
   AG          766     50.6      1,254       50.8             G         1,292       42.7   2,342   47.4   
   GG          263     17.4      544         22.0                                                         
  rs11125529                                                                                              
   AA          254     16.8      453         18.3     0.42    A         1,305       43.1   2,168   43.9   0.49
   AC          797     52.6      1,262       51.1             C         1,723       56.9   2,772   56.1   
   CC          463     30.6      755         30.6                                                         

**Abbreviations:** CHD, coronary heart disease; N/A, not available.

###### 

Effective allele ORs and adjusted ORs

               Gene     Effective allele   Other allele   OR (95% CI)            Adjusted OR (95%)
  ------------ -------- ------------------ -------------- ---------------------- ----------------------
  rs10936599   TERC     T                  C              0.907 (0.825--0.995)   0.942 (0.853--0.997)
  rs2736100    TERT     G                  T              1.013 (0.925--1.109)   1.003 (0.920--1.007)
  rs7675998    NAF1     A                  G              2.104 (1.887--2.345)   1.913 (1.702--2.121)
  rs9420907    OBFC1    A                  C              N/A                    N/A
  rs8105767    ZNF208   A                  G              0.965 (0.874--1.065)   0.982 (0.901--1.016)
  rs755017     RTEL1    A                  G              1.211 (1.106--1.327)   1.120 (1.007--1.204)
  rs11125529   ACYP2    C                  A              1.033 (0.943--1.131)   1.008 (0.931--1.073)

**Abbreviations:** OR, odds ratio; CI, confidence interval; N/A, not available.

###### 

Mean onset age of CHD for each genotype of rs7675998

  Genotype    Age (years) (mean ± SD)   *P*
  ----------- ------------------------- -------
  rs7675998                             0.012
   AA         52.6±10.4                 
   AG         54.2±11.3                 
   GG         59.5±9.2                  

**Abbreviations:** CHD, coronary heart disease; SD, standard deviation.
